1. Introduction {#sec1}
===============

Obstructive sleep apnea syndrome (OSAS) is characterized by recurrent episodes of partial or complete collapse of the upper airway during sleep, leading to oxyhaemoglobin desaturation, frequent arousals, and sleep fragmentation \[[@B1]\]. It is a common disorder, with prevalence estimated at 10--17% for men and 3--9% for women, among adults in the developed countries \[[@B2]\]. OSAS is associated with excessive daytime sleepiness, poor quality of life, reduced work productivity \[[@B3]\], increased overall morbidity, and mortality \[[@B4]\]. Evidence also supports the relationship between OSAS and arterial hypertension, coronary heart disease, heart failure, and arrhythmias \[[@B5], [@B6]\]. Previous reports suggest that heart disorders occur in approximately 40% of patients with OSAS \[[@B5]\]. Intermittent hypoxia triggered by apneic events, as well as abrupt reduction of the intrathoracic pressure and augmentation of the sympathetic tone, contribute to the pathogenesis of cardiovascular disease in OSAS \[[@B7]\]. However, OSAS and cardiovascular disease share common risk factors, such as obesity, hypertension, and diabetes \[[@B8]\]. Thus, the association between OSAS and cardiovascular disease may be attributed to either a clustering of risk factors present in both conditions, or to a real causal role. The aim of this study was to evaluate whether the estimated 10-year risk for cardiovascular morbidity and mortality, as assessed by Framingham Risk Score (FRS) and Systematic Coronary Risk Evaluation (SCORE), respectively, is increased in recently diagnosed patients with OSAS and to explore possible associations between those cardiovascular assessment risk scores with polysomnographic characteristics in OSAS.

2. Patients and Methods {#sec2}
=======================

Included were consecutive individuals referred to the sleep laboratory of our institution in a 6-month period, between January and June 2015, with symptoms suggestive of sleep-related breathing disorders. The study was performed in accordance with the Helsinki Declaration of Human Rights, as revised in 2013 \[[@B9]\], and patients provided their informed consent.

Exclusion criteria were age \> 65 years, history of stroke, cardiovascular disease and arrhythmias, chronic kidney disease, use of statins or aspirin, any chronic inflammatory disease, exclusively central apneas on polysomnography, diabetes, and endocrine disorders.

Information on previous medical history, current medication use, tobacco smoking, and alcohol consumption were recorded. Height, weight, body mass index (BMI) (weight (kg)/height (m)^2^), as well as neck, waist, and hip circumference and waist/hip ratio were measured using a standardized protocol.

Blood pressure was recorded in the sitting position after a 10 minute rest, as the average of 3 consecutive measurements separated by a 1 minute interval. Diagnosis of diabetes mellitus was based either on known medical history of diabetes or measurement of fasting plasma glucose ≥126 mg/dl \[[@B10]\].

Sleepiness was evaluated by the validated version of the Epworth sleepiness scale (ESS) in Greek language \[[@B11]\], a self-administered questionnaire evaluating the possibility of falling asleep in a variety of situations (maximum score: 24; score \>10 indicative of excessive daytime sleepiness). Pulmonary function testing, arterial blood gasses, and a 12-lead electrocardiographic examination before sleep study were also performed.

2.1. Polysomnography {#sec2.1}
--------------------

Overnight polysomnography (PSG) (Alice® 4, Philips Respironics, Murrysville, PA, USA), attended by an experienced technician, was performed from 22 : 00 to 06 : 00 hours. A standard montage of electroencephalogram, electroocculogram, electromyogram, and electrocardiogram signals was used. Pulse oximetry was registered and airflow was detected using combined oronasal thermistors. Thoracic cage and abdominal motion were recorded using inductive plethysmography, as previously described \[[@B12]\]. The polysomnographic recordings were manually scored according to the 2007 American Association of Sleep Medicine guidelines for the scoring of sleep and associated events \[[@B13]\]. The proportion of time spent in each stage of sleep was calculated as a percentage of total sleep time. Apnea was defined as 90% reduction in airflow for at least 10 sec \[[@B13]\]. Hypopnea was defined as a 30% reduction in airflow for at least 10 sec in combination with oxyhaemoglobin desaturation of at least 3% or an arousal registered by the electroencephalogram \[[@B13]\]. A central apnea was scored in the presence of cessation of airflow for 10 seconds or longer without an identifiable respiratory effort \[[@B13]\]. The apnea-hypopnea index (AHI) was calculated as the average number of apneas and hypopneas per hour of PSG-recorded sleep time \[[@B13]\]. Oxygen desaturation index (ODI) was calculated as the average number of arterial oxygen desaturations ≥ 3% per hour of sleep \[[@B13]\]. Sleep efficiency was defined as the ratio of total sleep time (TST) to time in bed (multiplied by 100 to yield a percentage).

OSAS was diagnosed when AHI was \>5/h, accompanied by related symptoms, and was graded as mild (AHI: 5--14.9/h), moderate (AHI: 15--29.9/h), or severe (AHI: \>30/h) \[[@B1]\].

2.2. Blood Samples {#sec2.2}
------------------

All blood samples were collected after at least 8 hours of overnight fasting, were immediately centrifuged (10 minutes at 3000 rpm), and were preserved at −80 C° until analysis. Fasting blood glucose, triglycerides, total cholesterol, and high- and low-density lipoprotein were calculated by a random-access chemistry analyzer (AU640; Olympus; Hamburg, Germany).

2.3. Cardiovascular Risk Assessment {#sec2.3}
-----------------------------------

The 10-year risk for cardiovascular disease was assessed using two validated prediction models: the low-risk Systematic Coronary Risk Evaluation (SCORE) and the Framingham Risk Score (FRS). The SCORE estimates the 10-year risk of fatal cardiovascular disease using an algorithm that considers parameters such as age, gender, total cholesterol, high-density lipoprotein cholesterol, systolic blood pressure, and smoking status \[[@B14]\]. Combining those parameters, SCORE values are reflecting the 10-year risk for cardiovascular mortality from a range of lower than 1% to greater than 15%. The FRS, which assesses the 10-year risk of developing cardiovascular disease in general and in specific of its components such as coronary heart disease, cerebrovascular disease, and heart failure, was calculated considering risk factors such as age, gender, total cholesterol and high-density lipoprotein cholesterol, systolic blood pressure, hypertension treatment, smoking status, and diabetes \[[@B15]\]. Risk groups were defined by risk percentages as follows: low  \<10%, intermediate 10--20%, high \>20%, and obtained only in patients without a history of cardiovascular disease.

2.4. Statistical Analysis {#sec2.4}
-------------------------

Analysis was performed using Statistical Package for Social Sciences version 17.0 (SPSS Inc. Released 2008. SPSS Statistics for Windows, Version 17.0. Chicago: SPSS Inc.). Continuous variables were tested for normality of distribution by the Kolmogorov--Smirnov test. Quantitative data with normal distribution were expressed as mean ± standard deviation (SD) and with skewed distribution as median (25th--75th percentile). Correlations were analyzed with Pearson\'s correlation coefficient, while in case of skewed distribution, the Spearman correlation coefficient was applied. Comparisons between means were explored with the Student\'s *t*-test, and for skewed distribution, the nonparametric Mann--Whitney test was applied. Associations between variables on univariate regression analysis, with a two-tailed *p* \< 0.05, were entered into multivariate models to determine the independent correlations with cardiovascular risk scores.

3. Results {#sec3}
==========

A total of 393 patients (288 males and 105 females) were included in the study. Patients were stratified, according to AHI, in 4 groups: control group (AHI \< 5 events/h), including 77 subjects (41 males and 36 females); mild OSAS (AHI 5--14.9 events/h), including 91 patients (64 males and 27 females); moderate OSAS (AHI 15--29.9 events/h), including 58 patients (42 males and 12 females); and severe OSAS (AHI \> 30 events/h), including 167 patients (141 males and 26 females). Mean age of the control group was significantly lower than that of any subgroup of OSAS patients (45.3 ± 10.1 for controls versus 48.8 ± 9.8 for mild OSAS, *p*=0.023; versus 53 ± 9.8 for moderate OSAS, *p* \< 0.001; and versus 51 ± 9.7 years for severe OSAS, *p* \< 0.001) while patients with severe OSAS had higher BMI compared with controls (35.5 ± 6.6 versus 32.5 ± 7.4 kg/m^2^, *p*=0.002). Anthropometric characteristics of participants are presented in [Table 1](#tab1){ref-type="table"}, while sleep characteristics are presented in [Table 2](#tab2){ref-type="table"}.

In all OSAS groups, mean systolic blood pressure was higher compared to controls ([Table 3](#tab3){ref-type="table"}). In severe OSAS, increased serum cholesterol and high-density lipoprotein cholesterol levels compared with controls were observed ([Table 3](#tab3){ref-type="table"}).

SCORE increased in line with OSAS severity and was higher compared to controls and among OSAS groups of increasing severity (0 (0-1) for controls versus 1 (0--2) for mild OSAS, *p*=0.001; versus 1 (0--3) for moderate OSAS, *p* \< 0.001; and versus 1.5 (1--3) for severe OSAS, *p* \< 0.001) ([Figure 1](#fig1){ref-type="fig"}).

Likewise, FRS increased in parallel with OSAS severity and was higher in OSAS patients than that of the control group (3 (1--5) for the control group versus 4 (1.5--7) for mild OSAS, *p*=0.004; versus 10 (2.5--13.5) for moderate OSAS, *p* \< 0.001; and versus 12 (5--15) for severe OSAS, *p* \< 0.001) ([Figure 2](#fig2){ref-type="fig"}). Results of laboratory analyses and measurements performed are presented in [Table 3](#tab3){ref-type="table"}.

In OSAS patients, a positive correlation between AHI and SCORE was revealed (*r*=0.251,  *p* \< 0.001) ([Figure 3](#fig3){ref-type="fig"}) as well as between AHI and FRS (*r*=0.291,  *p* \< 0.001) ([Figure 4](#fig4){ref-type="fig"}) and a negative correlation between FRS and sleep efficiency (*r*=−0.224,  *p*=0.006) ([Figure 5](#fig5){ref-type="fig"}). Results of the conducted correlation analyses between SCORE, FRS, anthropometric, and sleep parameters are presented in [Table 4](#tab4){ref-type="table"}.

After adjustment for age and BMI, SCORE was significantly correlated with age (*β*=0.587,  *p* \< 0.001), BMI (*β*=0.131,  *p*=0.005), and AHI (*β*=0.257,  *p* \< 0.001), while FRS was correlated with age (*β*=0.219,  *p* \< 0.001), BMI (*β*=−0.228,  *p* \< 0.001), and AHI (*β*=0.334,  *p* \< 0.001).

4. Discussion {#sec4}
=============

The current study demonstrates that the 10-year risk for cardiovascular morbidity and mortality, as expressed by the two multivariate risk models, FRS and SCORE, respectively, increases in accordance with OSAS severity. Moreover, an inverse association between the 10-year risk for cardiovascular disease and sleep efficiency was noticed.

FRS and SCORE constitute multivariate risk models which are assessing the 10-year risk for cardiovascular disease in individuals presented without established cardiovascular disease. Both point out the need of primary prevention for patients who are at high risk for future cardiovascular events, either fatal or nonfatal, such as coronary heart disease, stroke, heart failure, and intermittent claudication \[[@B14], [@B15]\]. Patients, who found to have an increased likelihood of cardiovascular morbidity and mortality, as assessed by those risk models, should receive hypertensive treatment, start on statin and aspirin therapy, and apply lifestyle modifications.

OSAS has been previously associated with increased morbidity and mortality related to cardiovascular disease, particularly coronary heart disease and stroke \[[@B5], [@B7], [@B8]\]. In a study \[[@B16]\] that included 114 OSAS patients (100 males and 14 females), 10-year risk for coronary heart disease in males was 13.9 ± 0.9%, (95% CI: 12.1--16.0) and for stroke was 12.3 ± 1.4%; (95% CI: 9.4--15.1), with a combined 10 year risk for stroke and CHD events of 32.9 ± 2.7%; (95% CI: 27.8--38.5) in males aged \> 53 years. In the same study, when patients were stratified according to their AHI, coronary heart disease risk did not significantly differ among groups \[[@B16]\]. However, in this study, HDL-C levels were not measured and were not considered in the risk prediction model; thus, results may tend to underestimate the true cardiovascular risk related to abnormal lipid status.

Similarly to our results, in a population-based study that included 904 patients classified according to FRS score, AHI was increased in the high-risk group compared to the intermediate- and low-risk groups (23.9 ± 2.8 versus 17.7 ± 1.8 versus 7.2 ± 0.5 events/h, resp., *p* \< 0.001) \[[@B17]\]. Sleep efficiency also differed between groups (67.6 ± 2.5% for the high-risk group; 78.4 ± 1.6% for the intermediate-risk group; and 82.9 ± 0.4% for the low-risk group, resp., *p* \< 0.001) \[[@B17]\]. After adjustment for confounding factors, age (*p* \< 0.001) and sleep efficiency (*p*=0.006) remained strongly associated with high-risk patients \[[@B17]\].

Wang et al. \[[@B18]\] divided 120 OSAS patients in 2 groups according to FRS score: low-risk group (with FRS \< 10) and non-low-risk group (with FRS ≥ 10). Subjects with higher FRS had a larger neck circumference (40.48 ± 2.80 versus 39.15 ± 4.31 cm, *p* \< 0.05), longer course of disease (12.77 ± 7.89 versus 9.36 ± 5.98 years, *p* \< 0.05), increased AHI (47.61 ± 25.63 versus 34.01 ± 25.72 events/h, *p* \< 0.01), lower minimum oxyhaemoglobin saturation during sleep (73.85 ± 11.10 versus 77.91 ± 9.77%, *p* \< 0.05), longer time with oxyhaemoglobin saturation \<90% (23.46 ± 24.46 versus 14.48 ± 18.85%, *p* \< 0.05), and higher ODI (49.62 ± 23.75 versus 39.01 ± 24.87 events/h, *p* \< 0.05) \[[@B18]\]. AHI was the most important determining factor for FRS (*t*=2.910,  *p*=0.004) \[[@B18]\].

In our study, an association between FRS score and sleep efficiency, an objective index of sleep quality, was observed. A number of studies examined the association between sleep efficiency and arterial blood pressure, often reporting conflicting results \[[@B19], [@B20]\]. Good sleep efficiency, defined as sleep efficiency \>90%, was less frequently observed among OSAS patients with cardiovascular disease (OR 0.45 (0.22--0.91)) \[[@B21]\].

In a study \[[@B22]\] that compared systolic arterial pressure and heart rate, nocturnal dipping between subjects with low and high sleep efficiency demonstrated that the group with low sleep efficiency presented a blunted dip of nocturnal systolic arterial pressure (10 ± 1 versus 14 ± 1%, *p*=0.04) and heart rate (12 ± 3 versus 21 ± 3%, *p*=0.03) compared with the high sleep efficiency group. Additionally, the low sleep efficiency group had higher mean nocturnal heart rate (63 ± 2 versus 55 ± 2 beats/min, *p*=0.02) \[[@B21]\]. In women, poor sleep quality has been associated with resistance to hypertensive treatment \[[@B23]\]. In the present study, sleep efficiency markedly decreased in the severe OSAS group, and in the same group, the percentage of slow-wave sleep was also reduced. Previous data showed that patients with reduced slow-wave sleep had decreased sympathetic activity during slow-wave sleep and increased risk of developing hypertension among elderly men \[[@B24], [@B25]\]. Thus, our findings further support the notion that sleep efficiency may be an important factor to be considered regarding the role of inadequate sleep in cardiovascular disease.

Certainly, our study is subject to some limitations. First, there was an over-representation of patients with severe OSAS in our sample, which was attributed to the distribution of subjects referred in a sleep laboratory with complaints of sleep-disordered breathing and increased likelihood of sleep apnea. We also acknowledge the fact that the performance of a single night PSG may influence our results since a single night recording has been associated with reduced sleep efficiency and fragmented sleep \[[@B26]\]. Moreover, evaluation of cardiovascular risk using these models is limited in a period time of only 10 years while the mean age of our sample size was relatively small. Thus, long-term cardiovascular assessment of young OSAS patients with lifetime risk models should be part of routine evaluation and preferred instead of the 10-year risk model. Finally, we did not examine the potential beneficial effect of continuous positive airway pressure (CPAP) treatment on those risk models, which could be possibly modified, especially in patients with good adherence, as it was demonstrated with single biomarkers associated with increased cardiovascular risk \[[@B27]\]. However and despite the above mentioned limitations, one of the major strengths of the present study is that it has used two different tools to evaluate cardiovascular risk, which resulted in similar findings, verifying the applicability of the selected models in our study \[[@B28]\].

In conclusion, the 10-year risk for cardiovascular morbidity, in a cohort of newly diagnosed OSAS patients, increases along with the severity of OSAS as indicated by AHI. Sleep physicians should bear this finding in mind, in order to seek for and eliminate risk factors for cardiovascular disease and to prevent future cardiovascular events in patients with OSAS. Further investigation on cardiovascular risk assessment based upon risk models with large epidemiological studies in OSAS patients is needed.
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###### 

Comparison of anthropometric characteristics between controls and obstructive sleep apnea syndrome (OSAS) patients.

                             Controls       Mild OSAS      Moderate OSAS   Severe OSAS    Controls versus mild OSAS   Controls versus moderate OSAS   Controls versus severe OSAS   Mild versus moderate OSAS   Mild versus severe OSAS   Moderate versus severe OSAS
  -------------------------- -------------- -------------- --------------- -------------- --------------------------- ------------------------------- ----------------------------- --------------------------- ------------------------- -----------------------------
  Number                     77             91             58              167            ---                         ---                             ---                           ---                         ---                       ---
  Gender (males/females)     41/36          64/27          42/16           141/26         **0.023**                   **0.020**                       **\<0.001**                   0.736                       **0.007**                 **0.05**
  Age (years)                45.3 ± 10.1    48.8 ± 9.8     53 ± 9.8        51 ± 9.7       **0.023**                   **\<0.001**                     **\<0.001**                   **0.011**                   0.088                     0.170
  BMI (kg/m^2^)              32.5 ± 7.4     32.9 ± 5.7     32.6 ± 5.8      35.5 ± 6.6     0.722                       0.917                           **0.002**                     0.809                       **0.002**                 **0.005**
  Neck circumference (cm)    41.2 ± 4.3     42.6 ± 3.7     42.3 ± 3.3      44.7 ± 4       0.058                       0.236                           **\<0.001**                   0.682                       **0.001**                 **0.003**
  Waist circumference (cm)   112.4 ± 18.2   114.5 ± 13.7   117.2 ± 15      121.1 ± 15.1   0.477                       0.226                           **0.002**                     0.399                       **0.007**                 0.221
  Hip circumference (cm)     116.7 ± 16.8   115.4 ± 10.6   117.5 ± 13.4    121.2 ± 14.8   0.596                       0.821                           0.094                         0.402                       **0.008**                 0.227
  WHR                        0.93 ± 0.06    0.98 ± 0.06    0.99 ± 0.07     1 ± 0.06       0.061                       **0.020**                       **0.001**                     0.740                       0.040                     0.796
  Smoking (%**)**            47.2           42.7           40.1            47.6           0.566                       0.453                           0.410                         0.695                       0.218                     0.367

BMI: body mass index; WHR: waist to hip ratio.

###### 

Comparison of sleep characteristics between controls and obstructive sleep apnea syndrome (OSAS) patients.

                         Controls            Mild OSAS           Moderate OSAS       Severe OSAS         Controls versus mild OSAS   Controls versus moderate OSAS   Controls versus severe OSAS   Mild versus moderate OSAS   Mild versus severe OSAS   Moderate versus severe OSAS
  ---------------------- ------------------- ------------------- ------------------- ------------------- --------------------------- ------------------------------- ----------------------------- --------------------------- ------------------------- -----------------------------
  TST (min)              294.7 ± 44.6        307.4 ± 43.8        302.9 ± 51.6        282.6 ± 73.6        0.224                       0.505                           0.097                         0.699                       **0.009**                 **0.047**
  N1 (%)                 13.5 (10.8--20.6)   14.1 (7.9--25.2)    22.1 (15.2--32.2)   23.4 (13.2--40.6)   0.467                       0.234                           0.528                         0.910                       0.721                     0.549
  N2 (%)                 55.1 ± 14.2         52.3 ± 17.5         52.1 ± 8.4          53.2 ± 12.2         0.471                       0.323                           0.466                         0.929                       0.787                     0.577
  N3 (%)                 9.1 (2--17.1)       6.1 (0--12)         9.8 (3--16.9)       7.2 (3.2--17.8)     0.065                       0.771                           0.602                         **0.047**                   **0.005**                 0.863
  REM (%)                11 (7.3--17.9)      10 (6--23.5)        13 (9.3--17.2)      9.1 (4.7--14.7)     0.494                       0.951                           0.386                         0.691                       0.307                     0.282
  AHI (events/h)         2 (1--3.5)          10 (6--13)          21.3 (18--27)       61.4 (45--75.7)     **\<0.001**                 **\<0.001**                     **\<0.001**                   **\<0.001**                 **\<0.001**               **\<0.001**
  ODI (events/h)         25.3 (14--46.7)     34.8 (10.8--50.7)   23.8 (12--60.2)     34.1 (12.7--68.7)   0.399                       0.323                           0.546                         0.813                       0.451                     0.508
  Aver. SpO~2~ (%)       92 ± 3.7            91.5 ± 4.1          92.2 ± 2.9          92.3 ± 2.7          0.547                       0.863                           0.713                         0.444                       0.200                     0.862
  Min. SpO~2~ (%)        76.7 ± 11           74.2 ± 15           80 ± 11             79.9 ± 10.2         0.419                       0.242                           0.123                         0.091                       **0.039**                 0.976
  Arousal index          18.1 (13.9--22.5)   22 (11.7--32.3)     27.9 (21.2--45.2)   23.1 (11.9--30.8)   0.166                       0.310                           0.388                         0.484                       **0.013**                 0.055
  Sleep efficiency (%)   78.5 ± 10.1         80 ± 9.4            80 ± 10.9           72.8 ± 15.8         0.514                       0.572                           **0.019**                     0.998                       **0.002**                 **0.009**
  ESS score              7.7 ± 5.6           8.9 ± 4.7           8.5 ± 5.2           10.8 ± 5.3          0.218                       0.490                           **0.001**                     0.757                       **0.018**                 **0.034**

AHI: apnea-hypopnea index; Aver. SpO~2~: average oxyhaemoglobin saturation; ESS: Epworth sleepiness scale; Min. SpO~2~: minimum oxyhaemoglobin saturation; N1: sleep stage 1; N2: sleep stage 2; N3: sleep stage 3; ODI: oxygen desaturation index; REM: rapid eye movement; TST: total sleep time.

###### 

Comparison of the laboratory measurements between controls and obstructive sleep apnea syndrome (OSAS) patients.

                          Controls        Mild OSAS          Moderate OSAS     Severe OSAS     Controls versus mild OSAS   Controls versus moderate OSAS   Controls versus severe OSAS   Mild versus moderate OSAS   Mild versus severe OSAS   Moderate versus severe OSAS
  ----------------------- --------------- ------------------ ----------------- --------------- --------------------------- ------------------------------- ----------------------------- --------------------------- ------------------------- -----------------------------
  FEV~1~ (% predicted)    99.3 ± 16.4     100.2 ± 18.3       100.4 ± 18.1      92.5 ± 21.9     0.787                       0.786                           0.051                         0.964                       **0.028**                 0.086
  FVC (% predicted)       94.4 ± 15.3     94.5 ± 15.5        94.7 ± 16.3       86.7 ± 20.8     0.963                       0.929                           **0.022**                     0.958                       **0.017**                 0.067
  FEV~1~/FVC (%)          84.9 ± 8.6      83.9 ± 9.1         86.1 ± 12.3       83.1 ± 12       0.553                       0.616                           0.341                         0.356                       0.662                     0.256
  pO~2~ (mmHg)            82.2 ± 14.2     82.7 ± 11.9        82.5 ± 11.6       76.4 ± 11       0.830                       0.902                           **0.008**                     0.946                       **0.001**                 **0.008**
  pCO~2~ (mmHg)           40.1 ± 3.4      40.3 ± 3.6         40.1 ± 3.7        41.7 ± 4        0.848                       0.923                           **0.020**                     0.800                       **0.033**                 **0.045**
  SBP (mmHg)              119.6 ± 14.3    125.9 ± 15.9       129.4 ± 15.5      134.8 ± 16.6    **0.008**                   **\<0.001**                     **\<0.001**                   0.183                       **\<0.001**               **0.032**
  DBP (mmHg)              77.7 ± 9.9      80.5 ± 8.7         80.1 ± 7.4        84 ± 9.5        0.052                       0.105                           **\<0.001**                   0.776                       **0.004**                 **0.002**
  Cholesterol (mg/dL)     214.2 ± 45.9    210.7 ± 37.8       222.8 ± 47        229.1 ± 39.9    0.591                       0.288                           **0.010**                     0.085                       **\<0.001**               0.317
  Triglycerides (mg/dL)   130 (89--165)   162 (110.5--230)   144 (74--180.5)   120 (94--195)   **0.049**                   0.712                           0.467                         0.144                       0.148                     0.663
  LDL-C (mg/dL)           131.3 ± 35.2    131.6 ± 30.8       141.9 ± 39.3      129.9 ± 35.8    0.964                       0.269                           0.853                         0.269                       0.814                     0.150
  HDL-C (mg/dL)           50 ± 12.4       49.5 ± 14          50.9 ± 12.1       43.8 ± 10.4     0.830                       0.649                           **\<0.001**                   0.525                       **\<0.001**               **\<0.001**
  Glucose (mg/dL)         101.2 ± 21.5    103.8 ± 22.3       98.3 ± 20.2       107.1 ± 21.8    0.671                       0.395                           0.174                         0.234                       0.361                     **0.047**
  SCORE                   0 (0--1)        1 (0--2)           1 (0--3)          1.5 (1--3)      **0.001**                   **\<0.001**                     **\<0.001**                   **0.049**                   **\<0.001**               **0.023**
  FRS                     3 (1--5)        4 (1.5--7)         10 (2.5--13.5)    12 (5--15)      **0.004**                   **\<0.001**                     **\<0.001**                   **0.030**                   **\<0.001**               **0.008**

DBP: diastolic blood pressure; FEV~1~: forced expiratory volume in 1st sec; FRS: Framingham Risk Score; FVC: forced vital capacity; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; pCO~2~: partial carbon dioxide pressure; pO~2~: partial oxygen pressure; SCORE: Systematic Coronary Risk Evaluation; SBP: systolic blood pressure.

###### 

Association between Systematic Coronary Risk Evaluation (SCORE), Framingham Risk Score (FRS), and anthropometric and sleep parameters.

                        SCORE    FRS                    
  --------------------- -------- ------------- -------- -------------
  Age                   0.652    **\<0.001**   0.233    **\<0.001**
  BMI                   −0.043   0.454         0.133    **0.019**
  Neck circumference    −0.012   0.870         0.072    0.336
  Waist circumference   −0.035   0.638         −0.029   0.701
  Hip circumference     −0.061   0.417         −0.103   0.166
  WHR                   0.047    0.525         0.131    0.077
  TST                   −0.054   0.509         −0.188   **0.021**
  N1                    −0.007   0.927         0.035    0.668
  N2                    −0.007   0.933         0.028    0.732
  N3                    0.070    0.394         0.033    0.684
  REM                   −0.031   0.706         −0.122   0.135
  AHI                   0.251    **\<0.001**   0.291    **\<0.001**
  ODI                   0.049    0.661         −0.129   0.245
  Aver. SpO~2~          0.131    0.107         0.132    0.104
  Min. SpO~2~           0.127    0.119         0.143    0.102
  Arousal index         −0.072   0.380         −0.127   0.122
  Sleep efficiency      −0.073   0.372         −0.224   **0.006**
  ESS score             0.103    0.156         0.108    0.135

AHI: apnoea hypopnea index; Aver. SpO~2~: average oxyhaemoglobin saturation; BMI: body mass index; ESS: Epworth sleepiness scale; Min. SpO~2~: minimum oxyhaemoglobin saturation; N1: sleep stage 1; N2: sleep stage 2; N3: sleep stage 3; ODI: oxygen desaturation index; REM: rapid eye movement; TST: total sleep time; WHR: waist to hip ratio.

[^1]: Academic Editor: Anne Knowlton
